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Abstract
The article presents a case of 64-year-old patient with years-long history of coronary artery disease, after several coro-
nary events and percutaneous coronary intervention, with a late diagnosis of familial hypercholesterolemia (FH). Based 
on the clinical case, the authors presented the current diagnostic possibilities and the importance of early FH diagnosis 
as well as modern lipid-lowering treatment with the use of PCSK9 inhibitors.
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Introduction
Since 2003–2005 (the WOBASZ study), hyperlipidemia has 
invariably been one of the most common risk factors of car-
diovascular diseases in Poland [1]. Genetically determined 
forms of the disease, such as familial hypercholesterolemia 
(FH), are observed among hyperlipidemias. The disease 
is still rarely diagnosed, i.a. due to the fact that until the 
present, the assessment of the lipidogram has only been 
routinely conducted in men over 40, post-menopausal 
women or women over 50 [2], which makes early detec-
tion of severe FH cases diffuclt. The newest guidelines of 
the European Society of Cardiology (ESC) [3] recommend 
tests for FH, including the assessment of the lipidogram in 
children aged 5 or less if there is a suspicion of a homo-
zygotic variant of the disease (class I recommendations, 
data credibility level: C).
Other factors which have an impact on the unsatisfac-
tory level of lipid disorders detection is the failure to con-
duct clinical assessment of patients according to the Dutch 
Lipid Clinic Network Scale (DLCNS) (Table 1), or the lack 
of genetic testing, despite their availability for tests reim-
bursed by the National Health Fund (NFZ, Narodowy Fun-
dusz Zdrowia). Patients bearing at least one of the listed 
elements should be referred for such tests [2]:
 — total cholesterol (TC) concentration in serum ≥ 310 mg/dL 
(≥ 8 mmol/L) in an adult patient or their family member;
 — premature coronary artery disease (CAD) in a patient 
or their family member (men < 55 years of age, women 
< 60 years of age);
 — tendon xanthelasmas in a patient or their family mem-
ber;
 — sudden cardiac death of a family member at a young 
age.
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The Third Declaration of Sopot [2] recommends the 
following treatment goals in terms of the concentration of 
low-density lipoprotein cholesterol (LDL-C):
 — below 1.8 mmol/L (< 70 mg/dL) in the group of high-
-risk patients;
 — below 1.4 mmol/L (< 55 mg/dL) in the group of patients 
bearing very high risk;
 — below 0.9 mmol/L (< 35 mg/dL) in the group of patients 
bearing extremely high risk;
This document distinguishes a group of patients bea-
ring extremely high cardiovascular risk, which is partially 
based on the recommendations of American endocrinolo-
gical societies [2]. The LDL-C goal in this group of patients, 
i.e. concentration below 0.9 mmol/L, was determined on 
the basis of prospective clinical studies on proprotein con-
vertase subtilisin/kexin type 9 inhibitors (PCSK9), which 
demonstrated cardiovascular benefits in secondary pre-
vention [2].
On the other hand, the most recent guidelines of the 
ESC Guidelines [3] do not include the group of patients 
with extremely high cardiovascular risk, while compared 
to the previous recommendations, treatment goals for 
particular risk groups have been changed. They are pre-
sented in Table 2.
On the basis of the clinical case in question, we are 
presenting the current state of knowledge concerning the 
possibilities of effective treatment of patients with HeFH 
in the era of PCSK9 inhibitors. 
Case report
In 2017, a man of 64, with 13-year-long history of cardiac 
disease, was admitted to a cardiac unit due to unstable 
angina. The patient had controlled hypertension, hyperlipi-
demia (TC 9.58 mmol/L, LDL-C 6.98 mmol/L and increased 
concentration of triglycerides (TG) — 2.88 mmol/L; Table 3), 
hyperuricemia (uric acid concentration 477 μmol/L) as well 
as level I obesity — body mass index (BMI) of 33.9 kg/m2.
Echocardiography showed segmental disorders of sys-
tolic function of the left ventricle with preserved global sys-
tolic function [ejection fraction (EF) 58%]. Coronary angiog-
raphy showed restenosis in the stent implanted in the left 
descending artery (LAD) with lumen stenosis of 70%, the 
right coronary artery (RCA) obstructed from segment 2, and 
without atherosclerotic lesions in the left circumflex (LCx) 
and intermediate branch (IM). Percutaneous coronary in-
tervention (PCI) of RCA was performed with an implantation 
of 3 stents releasing the medication: 3.0 × 13 mm, 2.5 × 
× 40 mm and, proximally, 3.5 × 20 mm with integrilin infu-
sion. The procedure was completed without complications.
The patient was diagnosed with coronary artery dise-
ase in 2004 when he suffered an infarction of the anterior 
and inferior wall, and was treated by means of PCI in LAD 
Hereditary forms of lipid disorders, especially homo- 
(HoFH) and heterozygotic familial hypercholesterolemia 
(HeFH), constitute a particular challenge in clinical practice.
Table 1. Criteria of the Dutch Lipid Clinic Network Scale (prepa-
red on the basis of [2, 3])
Clinical interview Number 
of points
Premature cardiovascular disease in the patient  
(men < 55 years of age, women < 60 years  
of age)
Premature cerebrovascular or peripheral vascu-
lar disease in the patient (men < 55 years of age 





First-degree relatives diagnosed with premature 
coronary artery disease (men < 55 years of age 
women < 60 years of age)
OR
First-degree relatives with LDL-C concentration 
> 95th percentile for the age and sex in a given 
country [> 190 mg/dL (> 4,9 mmol/L)]
First-degree relatives with tendon xanthelasmas 
and/or Corneal limbi in a patient < 45 years of age
OR
Children and adolescents < 18 years  
of age with LDL-C concentration > 95th percentile 
for age and sex in a given country  












LDL-C concentration (without treatment)
≥ 325 mg/dL (≥ 8.5 mmol/L)
251–325 mg/dL (6.5–8.4 mmol/L)
191–250 mg/dL (5.0–6.4 mmol/L)






Confirmed mutation of LDL, ApoB  
or PCSK9 receptor gene
8









LDL-C — low-density lipoprotein cholesterol; ApoB — apolipoprotein B; PCSK9 — proprotein conver-
tase subtilisin/kexin 9
260
Folia Cardiologica 2020, vol. 15, no. 3
www.journals.viamedica.pl/folia_cardiologica
Table 2. Allocation of patients to particular cardiovascular risk groups (prepared on the basis of [2, 3])
Levels of cardio-
vascular risk
The Third Declaration of Sopot [2] ESC Guidelines [3]
High • ≥ 2 risk factors and risk of 10–20% on the 
Pol-SCORE scale
• DM or CKD in 3rd–4th stage without other risk 
factors
Secondary treatment goal:
• non-HDL-C < 2.6 mmol/L (< 100 mg/dL)
• TC > 8 mmol/L (> 310 mg/dL), LDL-C > 4.9 mmol/L 
(> 190 mg/dL) or BP ≥ 180/110 mm Hg
• FH without significant risk factors
• DM duration ≥ 10 years, or with another co-existing risk 
factor, but without organ complications
• Moderate CKD (eGFR 30–59 mL/min/1.73 m2)
• Risk on the SCORE scale ≥ 5% and < 10% for a ten-year 
risk or critical CVD
Treatment goals: 
• primary: LDL-C < 1.8 mmol/L (< 70 mg/dL)
• secondary: non-HDL-C < 2.6 mmol/L (< 100 mg/dL)
  Apo-B < 80 mg/dL
Very high • ASCVD in patients in whom LDL-C < 70 mg/dL 
(< 1.8 mmol/L) was achieved and continuo-
usly maintained 
• Diagnosed ACS, coronary, carotid or peripheral 
artery disease
• Status post-revascularisation
• Risk on the Pol-SCORE scale > 20%
• DM or CKD in 3rd–4th stage and ≥ 1 risk factor
• FH
• History of premature ASCVD (men < 55 years 
of age, women < 65 years of age)
• Patients with DM or CKD at 3rd–4th stage diag-
nosed with CVD
Secondary treatment goal:
• non-HDL-C < 2.2 mmol/L (< 85 mg/dL)
• Clinically documented ASCVD after ACS (MI or UA), SA, 
post-revascularisation (PCI, CABG or other procedures), 
stroke or TIA and peripheral artery disease
• ASCVD documented in diagnostic imaging through the 
detection of substantial atherosclerotic plaque during 
angiography of coronary arteries or CT (polyvascular 
coronary artery disease with > 50% stenosis of the lu-
men of 2 main arteries), or in the ultrasound of carotid 
arteries
• DM with organ complications or with ≥ 3 main risk fac-
tors or with early onset of long-term (> 20 years) T1DM
• Acute CKD (eGFR < 30 mL/min/1.73 m2)
• Risk in the SCORE scale < 10% for 10-year-long risk or 
critical CVD
• FH with coexisting ASCVD or another risk factor
Treatment goals: 
• primary: LDL-C < 1.4 mmol/L (< 55 mg/dL)
• secondary:  non-HDL-C < 2.2 mmol/L (< 85 mg/dL)
  Apo-B < 65 mg/dL)
Extremely high • History of numerous cardiovascular events 
and/or revascularisation
• PCI of the main left coronary artery trunk  
and/or polyvascular coronary artert disease 
with complex angioplasty
• Generalised atherosclerosis of multiple vascu-
lar beds with additional risk factors
• Progression of ASCVD in patients in whom 
LDL-C < 55 mg/dL (< 1.4 mmol/L) was  
achieved and continuously maintained
Secondary treatment goal:
• non-HDL-C < 1.7 mmol/L (< 65 mg/dL)
ACS — acute coronary syndrome; ApoB — apolipoprotein B; ASCVD — atherosclerotic cardiovascular disease; BP — blood pressure; CABG — coronary artery bypass graft surgery; CKD — chronic kidney 
disease; CT — computed tomography; CVD — cardiovascular disease; DM — diabetes mellitus; eGFR — estimated glomerular filtration rate; ESC — European Society of Cardiology; FH — familial hypercholeste-
rolemia; HDL-C — high-density lipoprotein cholesterol; LDL-C — low-density lipoprotein cholesterol; MI — myocardial infarction; PCI — percutaneous coronary intervention; SA — stable angina; SCORE — Syste-
matic COronary Risk Estimation; T1DM — type 1 DM; TIA — transient ischemic attack; UA — unstable angina; USG — ultrasonography
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stenosis of the right posterior-lateral (diameter < 1.5 mm) 
branch of RCA. The results of the implantation of stents in 
LAD and LCx were also good. The patient was referred to 
further conservative treatment. 
Since the most recent PCI in 2017, the patient has been 
receiving acetylsalicylic acid in the dose of 75 mg, 25 mg 
of metoprolol, 5 mg of ramipril, 20 mg/day of pantoprazo-
le and trimethazidine in the dose of 35 mg/twice a day as 
well as intensive lipid-lowering treatment — 80 mg of ator-
vastatin + 10 mg of ezetimib once a day. Eight months and 
one year after the implementation of lipid-lowering treat-
ment the lipidogram was performed again. The results of 
the examination are presented in Table 3.
The application of combined therapy did not contribute 
to the achievement of treatment goals neither in relation to 
LDL-C, nor non-HDL-C, both according to the ESC guidelines 
concerning high cardiovascular risk and the Third Declara-
tion of Sopot concerning patients with extremely high risk.
New options for the treatment  
of lipid disorders
Lifestyle modification, particularly with regard to diet and 
physical activity, lies at the basis of the pyramid of lipid 
interventions. It is followed by statin treatment, intensive 
statin therapy and combined lipid-lowering treatment [2]. 
A new group of medications — PCSK9 inhibitors — has been 
for the first time included in the newest ESC guidelines for 
the treatment of lipid disorders [2]. So far, researchers have 
studied and documented benefits related to lowered risk 
of cardiovascular death, infarction, stroke, hospitalisation 
due to unstable angina (UA) or coronary artery revascula-
risation — hazard ratio (HR) [95% confidence interval (CI)] 
compared to placebo 0.85 (0.79–0.92) for evolocumab [5] 
and HR (95% CI) compared to placebo 0.85 (0.78–0.93) 
for alirocumab [6].
Proprotein subtilisin/kexine type 9 convertase is a pro-
tein which participates in the metabolism of LDL receptors 
(LDLR) through binding with them and stimulation of en-
docytosis of the LDLR-PCSK9 complex and degradation of 
LDLR in lysosome. On the other hand, PCSK9 inhibitors are 
monoclonal antibodies for PCSK9, which lead to a decrease 
in LDLR degradation and cause a decrease in LDL-C con-
centration by 60% on average regardless of another lipid-
-lowering treatment conducted simultaneously [7].
The RUTHERFORD-2 (Reduction of LDL-C With PCSK9 In-
hibition in Heterozygous Familial Hypercholesterolemia 
Disorder Study-2) study teremined the effectiveness of evo-
locumab in lowering LDL-C concentration in HeFH patients 
by 59–68% [8]. In turn, the ODDYSEY FH I (Efficacy and Sa-
fety of Alirocumab (SAR236553/REGN727) Versus Place-
bo on Top of Lipid-Modifying Therapy in Patients With He-
terozygous Familial Hypercholesterolemia Not Adequately 
with the implantation of a medication-releasing stent as 
well as PCI in RCA and IM with the implantation of metal 
stents. In the following years, the patient underwent the 
following PCIs with simultaneous implantation of medica-
tion-releasing stents: LAD in 2007, RCA in 2014 and LCx in 
2016. The patient had 9 stents altogether implanted into 
coronary arteries.
Moreover, patient’s father and brother suffered from 
premature CAD:
 — the brother suffered an infarction at the age of 45 and 
died of infarction at the age of 57;
 — the father suffered an infarction at the age of 48 and 
died of another infarction at the age of 67.
Based on patient’s history and physical examination, 
he was assessed in accordance with the DLCNS and diag-
nosed with probable FH — with a score of 8 points. 
 — premature CAD — 2 points;
 — premature CAD in first-degree relatives — 1 point;
 — LDL-C concentration of 6.98 mmol/L — 5 points.
In addition, a DNA analysis in search for the most com-
mon mutations in Poland, i.e. p.G592E of the LDRL gene 
and p.R3500Q of the APOB gene, was conducted to confirm 
clinically diagnosed FH. The mutations were not detected. 
Further molecular tests in search for other mutations of 
the LDLR and MTHFR genes were planned, and presen-
ce of mutation c.415G>C in exone 4 of LDLR gene, which 
confirms the diagnosis of HeFH form, was documented. 
The patient was informed about the necessity to conduct 
genetic tests in his first-degree relatives.
In March 2019, due to short-term coronary-related 
symptoms in stressful situations, the patient underwent 
angiography computed tomography (angio-CT), which sho-
wed progression of CAD — signs of restenosis in the stent 
implanted in LAD causing narrowing of the lumen to 50% 
as well as a narrowing to 60–70% in the artery behind the 
stent, narrowing of the IM ostium to 50% and narrowing in 
the first segment of RCA to 50–60%; the coronary artery 
calcium score was 369 j.A. The patient was qualified for 
the assessment of the functional extent of myocardial is-
chaemia with the use of the single-photon emission com-
puted tomography (SPECT).
Resting perfusion scintigraphy of the heart showed es-
tablished perfusion disorders encompassing the apex, an-
terior-septal wall and the parabasal section of the inferior 
wall (25–30%), worsening during the physical test in the 
area of parabasal and central segment of the inferior wall 
and adjacent segments of the inferior-lateral wall (Figure 1) 
which constituted 10%. In accordance with the current ESC 
guidelines for chronic coronary syndromes [4], the patient 
was referred for follow-up coronary angiography which sho-
wed a 50–70% stenosis of the central part of the interme-
diate artery, atherosclerotic plaque in the proximal segment 
of RCA with a narrowing to 50% as well as peripheral 90% 
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Controlled With Their Lipid-Modifying Therapy) study estab-
lished that the effectiveness of alirocumab ranged from 
51–58% in the same group of patients [9]. It is also worth 
noting that PCSK9 inhibitors are well tolerated. Compari-
son of selected aspects of statin and PCSK9 inhibitor tre-
atment is presented in Table 4.
There are two PCSK9 inhibitors available in the Polish 
market — alirocumab and evolocumab. They are admini-
stered subcutaneously; evolocumab usually in the dose of 
140 mg every 2 weeks [10] and alirocumab usually in the 
dose of 75 or 150 mg every 2 weeks [10].
Discussion
The presented clinical case constitutes an example of the 
application of a scale of the World Health Organization 
— the Dutch Lipid Clinic Network, a useful tool in clinical 
practice which enables the diagnosis of FH. It is esti-
mated that the incidence of FH in Europe amounts to 
1/500–1/2,000 people, and in most countries the per-
centage of diagnosed patients is less than 1% [11]. The 
estimated number of people living with HeFH in Poland 
ranges from 76,860 to 192,150 people, however, due 
to the lack of a register of FH patients, it is impossible 
to determine the number of diagnosed patients. Due to 
the fact that outpatient assessment of the parameters 
which constitute an element of the WHO scale (the Dutch 
Lipid Clinic Network) is easy, it is possible to increase the 
number of people in whom FH is diagnosed. The 10% 
increase in the CAD risk in HeFH patients as well as the 
incidence of premature CAD, at the level of 50% in men 
and 25% in women without treatment [2], emphasises 
Table 3. Comparison of lipidogram results before and after the implementation of intensive lipid-lowering treatment
Assessed parameter October 3, 2017 November 2, 2017 2018
TC concentration [mmol/L] 9.58 5.87 4.53
LDL-C concentration [mmol/L] 6.98 3.69 2.61
HDL-C concentration [mmol/L] 1.29 1.11 1.11
TG concentration [mmol/L] 2.88 2.34 1.54
Non-HDL concentration [mmol/L] 8.29 4.76 3.42
AlAT activity [U/L] 48 – 40
TC — total cholesterol; LDL-C — low-density lipoprotein cholesterol; HDL-C — high-density lipoprotein cholesterol; TG — triglycerides; AlAT — alanine aminotransferase
Figure 1. Result of perfusion scintigraphy of the heart conducted in 2019
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the significance of early diagnosis and implementation of 
treatment. Cascade diagnostics including the assessment 
of TC and LDL-C concentrations as well as genetic test-
ing, conducted in the relatives of the identified proband, 
constitutes the most effective method of detecting new 
FH cases. The current ESC guidelines for FH diagnosis 
recommend the performance of genetic tests, if it is 
possible, to confirm the clinical diagnosis in accordance 
with the DLCNS, classifying it as class I recommendation 
with data reliability level C [3].
Due to the lack of diagnosis for FH, the patient in que-
stion had been treated with weak statins for many years, 
which did not bring the expected results — neither clinical 
nor in terms of LDL-C concentration. After the implemen-
tation of intensive lipid-lowering treatment (atorvastatin 
80 mg + ezetimib 10 mg) it was observed that the patient 
tolerated it well, but the treatment goal for LDL-C remained 
unachieved. In addition, despite the co-existing metabolic 
and cardiovascular diseases, the patient was not subjec-
ted to multi-factor treatment. For years, despite the diagno-
sis of hyperurycemia, he did not take medication lowering 
the concentration of uric acid, nor was he diagnosed for 
obstructive night apnea, despite the symptoms indicating 
the existence of this clinical problem.
It stems from the above that there is a need for con-
tinuous education on cardiovascular risk factors and FH. 
There is an Association of Patients with Familial Hyperlipide-
mia in Gdańsk [12], the primary aims of which are effective 
prevention and health education leading to raising aware-
ness of the disease in the society and its early diagnosis. 
The activities of the Organisation include not only actions 
such as annual meetings on the occasion of the Familial 
Hypercholesterolemia Awareness Day, but also provide con-
stant access to information about the disease as well as 
the possibilities concerning prevention and treatment via 
its website, in order to provide patients with the best men-
tal support in their struggles with the disease. The medica-
tion programme for HF patients which exists in Poland [13] 
contains restrictive criteria concerning the effectiveness of 
lowering of LDL-C concentration up to date — LDL-C above 
160 mg/dL despite diet and:
 — intensive treatment with statins in maximum doses, i.e. 
atrovastatin 80 mg or rosuvastatin 40 mg, and then 
atrovastatin 40–80 mg or rosuvastatin 20–40 mg in 
combination with ezetimib 10 mg, administered for 
6 months in total, including combined treatment for at 
least one month;
 — or very intensive treatment with statins at maximum-
-tolerated doses, and subsequently in combination with 
ezetimib 10 mg, administered for 6 months in total, 
including combined treatment for at least one month.
Despite the lack of effectiveness of the so-far admini-
stered combined treatment, the above-described patient 
cannot be treated with PCSK9 inhibitors due to the high 
cost of the treatment and the fact that he cannot be qua-
lified for the programme as the criterion of LDL-C concen-
tration is not met.
Conclusions
The Dutch Lipid Clinic Network Scale is an easy and effec-
tive tool in the estimation of FH probability. However, due 
to excessively narrow criteria of the programme and the 
high cost of the treatment when it is not reimbursed, the 
access to effective treatment of hypercholesterolemia with 
the use of PCSK9 inhibitors remains limited.
Conflict of interest
Authors do not declare the conflict of interest.
Table 4. Comparison of selected aspects of treatment with statins and treatment with proprotein convertase subtilisin/kexin type 9 
(PCSK9) inhibitors






Adverse effects  
of treatment [16]
Statin [14] Lowering of LDL-C 
concentration by 
30–50%
In 80% of patients the 
LDL-C concentration 
of < 100 mg/dL is not 




Muscle inflammation and rhabdomyolysis, 
liver dysfunction, myopathies, proteinuria, 




Lowering of LDL-C 
concentration by 
46% (alirocumab) to 
56.1% (evolocumab)
Lowering of LDL-C 





Gastrointestinal disorders, infections and 
infestations, musculoskeletal, cutaneous or 
subcutaneous tissue disorders (alirocumab)
Nasopharyngitis, infections of the upper 
respiratory tract, flu-like symptoms and back 
pain (evolocumab)
HeFH — heterozygous familial hypercholesterolemia; LDL-C — low-density lipoprotein cholesterol
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Streszczenie
W artykule opisano przypadek 64-letniego pacjenta z wieloletnim wywiadem choroby wieńcowej, po licznych incydentach 
wieńcowych i przezskórnej interwencji wieńcowej, u którego późno zdiagnozowano hipercholesterolemię rodzinną (FH). 
Na podstawie przypadku klinicznego przedstawiono aktualne możliwości diagnostyczne i istotność wczesnego rozpo-
znania FH oraz nowoczesną terapię hipolipemizującą z wykorzystaniem inhibitorów PCSK9.
Słowa kluczowe: hipercholesterolemia rodzinna, inhibitory PCSK9, skala the Dutch Lipid Clinic Network
Folia Cardiologica 2020; 15, 3: 258–264
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